The effect of a monoclonal antibody coupled to ricin a chain-derived peptides on endothelial cells in vitro: Insights into toxin-mediated vascular damage

Experimental Cell Research

Volumn 258, Issue 2, 2000, Pages 417-424

  Baluna, Roxana ^a   Coleman, Elaine ^a   Jones, Chandria ^a   Ghetie, Victor ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Endothelial cells; Immunotoxins disintegrins; Vascular leak syndrome

Indexed keywords

MONOCLONAL ANTIBODY; RICIN;

ANTIGEN BINDING; ARTICLE; BLOOD VESSEL INJURY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); LACTATE DEHYDROGENASE-ELEVATING VIRUS;

EID: 0034255636     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.4954     Document Type: Article

References (50)

1. Vitetta E. S., Thorpe P. E., Uhr J. W. Immunotoxins: Magic bullets or misguided missiles. Immunol. Today. 14:1993;252-259.
2. Amlot P. L., Stone M. J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P. E., Uhr J. W., Vitetta E. S. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82:1993;2624-2633.
3. Stone M. J., Sausville E. A., Fay J. W., Headlee D., Collins R. H., Figg W. D., Stetler-Stevenson M., Jain V., Jaffe E. S., Solomon D., Lush R. M., Senderowicz A., Ghetie V., Schindler J., Uhr J. W., Vitetta E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 88:1996;1188-1197.
4. Grossbard M. L., Lambert J. M., Goldmacher V. S., Spector N. L., Kinsella J., Eliseo L., Coral F., Taylor J. A., Blattler W. A., Epstein C. L., Nadler L. M. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol. 11:1993;726-737.
5. Frankel A. E., Tagge E. P., Willingham M. C. Clinical trials of targeted toxins. Semin. Cancer Biol. 6:1995;307-317.
6. Vallera D. A. Immunotoxins: Will their clinical promise be fulfilled? Blood. 83:1994;309-317.
7. Sausville E. A., Headlee D., Stetler-Stevenson M., Jaffe E. S., Solomon D., Figg W. D., Herdt J., Kopp W. C., Rager H., Steinberg S. M., Ghetie V., Schindler J., Uhr J., Wittes R. E., Vitetta E. S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood. 85:1995;3457-3465.
8. Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W., Thorpe P. E. A phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51:1991;4052-4058.
9. Baluna R., Vitetta E. S. Vascular leak syndrome: A side effect of Immunotherapy. Immunopharmacology. 37:1996;117-132.
10. Engert A., Sausville E. A., Vitetta E. S. Frankel A. E. Clinical Applications of Immunotoxins. 1997;13-33 Scientific Publishing Services, Charleston.
11. Sausville E. A., Vitetta E. S. Grossbard M. L. Monoclonal Antibody-Based Therapy of Cancer. 1997;81-89 Dekker, Boston.
12. Soler-Rodriguez A. M., Ghetie M. A., Oppenheimer-Marks N., Uhr J. W., Vitetta E. S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp. Cell Res. 206:1993;227-234.
13. Baluna R., Ghetie V., Oppenheimer-Marks N., Vitetta E. S. Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int. J. Immunopharmacol. 18:1996;355-361.
14. Lindstrom A. L., Erlandsen S. L., Kersey J. H., Pennell C. A. An in vitro model for toxin-mediated vascular leak syndrome - Ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood. 90:1997;2323-2334.
15. Baluna R., Rizo J., Gordon B. E., Ghetie V., Vitetta E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA. 96:1999;3957-3962.
16. Komoriya A., Green L. J., Mervic M., Yamada S. S., Yamada K. M., Humphries M. J. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively-spliced type III connecting segment domain of fibronectin is leucin-aspartic acid-valine. J. Biol. Chem. 266:1991;15075-15079.
17. Clements J. M., Newham P., Shepherd M., Gilbert R., Dudgeon T. J., Needham L. A., Edwards R. M., Berry L., Brass A., Humphries M. J. Identification of a key intergrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J. Cell Sci. 107:1994;2127-2135.
18. Saba T. M. Mosher D. F. Fibronectin. 1989;395-439 Academic Press, San Diego.
19. Garcia-Pardo A., Wayner E. A., Carter W. G., Ferreira O. C. Human B lymphocytes define an alternative mechanism of adhesion to fibronectin. J. Immunol. 144:1990;3361-3366.
20. Riddles P. W., Blakeley R. L., Zerner B. Ellman's reagent: 5,5′-dithiobis(2-nitrobenzoic acid) - a reexamination. Anal. Biochem. 94:1979;75-81.
21. Mlsna D., Monzingo A. F., Katzin B. J., Ernst S., Robertus J. D. Structure of recombinant ricin a-chain at 2.3 angstrom. Protein Sci. 2:1993;429-435.
22. Makarem R., Humphries M. J. LDV: A novel cell adhesion motif recognized by the integrin α4β1. Biochem. Soc. Trans. 19:1991;380S-382S.
23. Wayner E. A., Kovach N. L. Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J. Cell Biol. 116:1992;489-497.
24. Saba T. M., Jaffe E. Plasma fibronectin (opsonic glycoprotein): Its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am. J. Med. 68:1980;577-594.
25. Lampugnani M. G., Resnati M., Dejana E., Marchisio P. C. The role of integrins in the maintenance of endothelial monolayer integrity. J. Cell Biol. 112:1991;479-490.
26. Luscinskas F. W., Lawler J. Integrins as dynamic regulators of vascular function. FASEB J. 8:1994;929-938.
27. Ingber D. E. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc. Natl. Acad. Sci. USA. 87:1990;3579-3583.
28. Coulson B. S., Londrigan S. L., Lee D. J. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. Proc. Natl. Acad. Sci. USA. 94:1997;5389-5394.
29. Keppler-Hafkemeyer A., Brinkmann U., Pastan I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry. 37:1998;16934-16942.
30. Morimoto H., Bonavida B. Diphtheria toxin and Pseudomonas A toxin-mediated apoptosis: ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-α J. Immunol. 149:1992;2089-2094.
31. Chang M. P., Bramhall J., Graves S., Bonavida B., Wisnieski B. J. Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. J. Biol. Chem. 264:1989;15261-15267.
32. Kochi S. K., Collier J. DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp. Cell Res. 208:1993;296-302.
33. Willingham M. C., Tagge D. U., Brothers T. E., Frankel A. E. Fourth International Symposium on Immunotoxins. 1995;. p. 116-116.
34. Kumar S. Mechanisms mediating caspase activation in cell death. Cell Death Differ. 6:1999;1060-1066.
35. Slee E. A., Adrain C., Martin S. J. Serial killers: Ordering caspase activation events in apoptosis. Cell Death Differ. 6:1999;1067-1074.
36. McLane M. A., Marcinkiewicz C., Vijay-Kumar S., Wierzbicka-Patynowski I., Niewiarowski S. Viper venom disintegrins and related molecules. Proc. Soc. Exp. Biol. Med. 219:1998;109-119.
37. Huang T.-F. What have snakes taught us about integrins. Cell. Mol. Life Sci. 54:1998;527-540.
38. 3 subunit. Exp. Cell Res. 225:1996;132-142.
39. Danen E. H. J., Marcinkiewicz C., Cornelissen I., van Draats A. A., Pachter J. A., Ruiter D. J., Niewiarowski S., van Muijen G. N. P. The disintegrin eristostatin interferes with ingegrin α4β1 function and with experimental metastasis of human melanoma cells. Exp. Cell Res. 238:1998;188-196.
40. Marcinkiewicz C., Calvete J. J., Marcinkiewicz M. M., Raida M., Vijay-Kumar S., Huang Z., Lobb R. R., Niewiarowski S. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner. J. Biol. Chem. 274:1999;12468-12473.
41. 3 antagonist and inducing apoptosis. Blood. 292:1998;3268-3276.
42. Pollman M. J., Naumovski L., Gibbons G. H. Vascular cell apoptosis: Cell type-specific modulation by transforming growth factor-B1 in endothelial cells versus smooth muscle cells. Circulation. 99:1999;2019-2026.
43. Polunovsky V. A., Wendt C. H., Ingbar D. H., Peterson M. S., Bitterman P. B. Induction of endothelial cell apoptosis by TNF α: Modulation by inhibitors of protein synthesis. Exp. Cell Res. 214:1994;584-594.
44. Dhanabal M., Ramchandran R., Waterman M. J. F., Lu H., Knebelmann B., Segal M., Sukhatme V. P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274:1999;11721-11726.
45. Buckley C. D., Pilling D., Henriquez N. V., Parsonage G., Threlfall K., Scheel-Toellner D., Simmons D. L., Akbar A. N., Lord J. M., Salmon M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 397:1999;534-539.
46. Fukai F., Mashimo M., Akiyama K., Goto T., Tanuma S., Katayama T. Modulation of apoptotic cell death by extracellular matrix proteins and a fibronectin-derived antiadhesive peptide. Exp. Cell Res. 242:1998;92-99.
47. Lu X., Rahman S., Kakkar V. V., Authi K. S. Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin. J. Biol. Chem. 271:1996;289-294.
48. Zhang X.-P., Kamata T., Yokoyama K., Puzon-McLaughlin W., Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (Metargidin, ADAM-15) with integrin αvβ3. J. Biol. Chem. 273:1998;7345-7350.
49. Marcinkiewicz C., Vijay-Kumar S., McLane M. A., Niewiarowski S. Significance of RGD loop and c-terminal domain of echistatin for recognition of αIIbβ3 and αvβ3 integrins and expression of ligand-induced binding site. Blood. 90:1997;1565-1575.
50. McLane M. A., Vijay-Kumar S., Marcinkiewicz C., Calvete J. J., Niewiarowski S. Importance of the strucutre of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of αIIbβ3 and αvβ3 integrins. FEBS Lett. 391:1996;139-143.